Anbio Biotechnology Class A Ordinary Shares
Price Action
Technical Summary
CONSOLIDATINGAnbio Biotechnology Class A Ordinary Shares is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 46), showing significant lag compared to the market leaders. Earnings contraction of 267% provides fundamental context to the price action. Investors should exercise caution due to high volatility (153% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $27.97 | +4.41% | ABOVE |
| 50 SMA | $25.36 | +15.15% | ABOVE |
| 100 SMA | $27.27 | +7.08% | ABOVE |
| 150 SMA | $27.01 | +8.12% | ABOVE |
| 200 SMA | $31.57 | -7.49% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is NNNN in an uptrend right now?
NNNN has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is NNNN overbought or oversold?
NNNN's RSI (14) is 70. The stock is in neutral territory, neither overbought nor oversold.
Is NNNN outperforming the market?
NNNN has a Relative Strength (RS) Rating of 46 out of 99. NNNN is currently lagging the broader market.
Where is NNNN in its 52-week range?
NNNN is trading at $29.20, which is 52% of its 52-week high ($55.65) and 46% above its 52-week low ($6.24).
How volatile is NNNN?
NNNN has a Beta of 0.58 and 52-week volatility of 153%. It's less volatile than the S&P 500 - generally more stable.